Venue suggestions

Venue Recommendations

as_is

None. The editor's verdict is "major," and the panel identified load-bearing deficits in statistical reporting, claim calibration, and reproducibility that preclude acceptance at any peer-reviewed venue in its current form. Submission to In Silico or comparable outlets would invite public criticism on these points and would not advance the work.

---

after_revision

Nature Immunology or Immunity

• Fit: Both journals prioritize mechanistic immunology and stromal biology in chronic inflammation. This manuscript, once the Fig. 1 statistics are disambiguated and corrected, the explant claims are reframed as acute suppression rather than reversal, and the NOTCH3→NGF axis is properly contextualized against developmental precedent, sits squarely in their scope. The paired-biopsy spatial transcriptomics, the breadth of gain/loss-of-function validation, and the FDA-approved drug lead are all signature strengths for these venues.
• Odds after revision: Moderate (40–50%). The underlying biology is solid and the therapeutic angle is concrete, but the paper will face competition from studies with animal models or clinical validation. If the corrected Fig. 1 analysis holds and the remission-stratification claim is either supported or removed, the bar is met.

Science Translational Medicine

• Fit: This venue explicitly values mechanism-to-therapy pipelines. The progression from spatial transcriptomics → mechanistic cell biology → pharmacology in human tissue → FDA-approved drugs is exactly the translational arc STM seeks. The caveat is that the current explant data (3 days, ex vivo) do not yet constitute clinical validation, so positioning will matter: the paper should frame itself as a preclinical lead for future in vivo or clinical work, not as a therapeutic proof.
• Odds after revision: Moderate (35–45%). STM is highly competitive and will want either stronger in vivo data or a clearer path to clinical translation. If the authors can add even a brief dose–response or durability arm in explants, or partner with a clinical team on a small biomarker study, odds improve substantially.

Journal of Experimental Medicine or EMBO Journal

• Fit: Both are strong homes for mechanistic stromal biology and vascular immunology. JEM in particular has published extensively on fibroblast–endothelial crosstalk in RA. The spatial transcriptomics + explant pharmacology combination is well-suited to either venue's audience.
• Odds after revision: Moderate (40–50%). These are slightly less translational than STM but more forgiving of preliminary pharmacology if the mechanism is airtight. The required revisions (statistics, claim calibration, reproducibility) are all within scope; the main risk is that a reviewer will demand animal data. If the authors can show that the NOTCH3→NGF→NGFR axis is not simply recapitulating known developmental biology, odds improve.

---

alternative

bioRxiv (with In Silico overlay review)

• Rationale: If the required revisions are substantial and the authors wish to establish priority and gather feedback before a high-stakes submission, posting on bioRxiv with a concurrent In Silico review is a sensible intermediate step. In Silico's public, transparent review process is well-suited to this manuscript's strengths (broad experimental triangulation, concrete therapeutic lead) and will expose the remaining weaknesses to the community in a way that informs revision. This is not a fallback but a strategic choice.

Arthritis & Rheumatology or Annals of the Rheumatic Diseases

• Fit: These are the field's flagship journals for RA pathobiology. The spatial transcriptomics cohort and the NOTCH3–neurotrophin axis are both novel contributions to RA mechanistic understanding. However, both journals typically expect either larger clinical cohorts, animal models, or a clearer therapeutic endpoint (e.g., a phase 1b trial or a biomarker-driven patient stratification).
• Odds after revision: Moderate (45–55%) at A&R, lower (30–40%) at ARD, because ARD leans more clinical. If the authors can add a small validation cohort or an animal model of RA (even a proof-of-concept in a standard model like collagen-induced arthritis), either venue becomes realistic. Without that, A&R is the better fit because it tolerates more mechanistic depth and less clinical maturity.

eLife

• Fit: eLife values rigorous, well-controlled mechanistic work and explicitly welcomes papers that are strong on biology but preliminary on translation. The spatial transcriptomics, the NOTCH3–NGF–NGFR axis, and the explant pharmacology all meet eLife's bar for novelty and rigor. The venue is also known for transparent, constructive peer review and for publishing detailed methods.
• Odds after revision: Moderate (45–55%). eLife will likely ask for the same revisions as the current panel (statistics, claim calibration, reproducibility), but is less likely to demand animal data or clinical validation as a condition of acceptance. This is a good fallback if Nature Immunology or STM decline.

---

Notes on Revision Strategy

1. Priority order for submission after revision: Nature Immunology or Immunity (highest impact, best fit for stromal immunology), then Science Translational Medicine (if the authors can strengthen the pharmacology arm), then eLife or EMBO Journal (strong backup, more forgiving of preliminary translation).

2. The remission-stratification claim is a critical juncture. If the stratified analysis supports the claim, the paper's motivating narrative (vascular maturation persists despite treatment even in responders) is much stronger and will appeal to high-impact venues. If it does not, the claim must be removed entirely; hedging it will invite criticism. The authors should run this analysis first and let the result guide the revision scope.

3. The "reversal" → "acute suppression" reframing is non-negotiable but is a straightforward textual fix. It does not require new experiments, only honest language. Once made, it will actually strengthen the paper's credibility because it acknowledges the limits of the current data and sets up a clear path for future work (durability, dedifferentiation vs. selective loss, healthy-donor comparisons).

4. Data deposition is essential. Spatial transcriptomics and bulk RNA-seq data are now expected to be public or in a controlled-access repository (GEO, ArrayExpress, or the authors' institution). Without accession numbers, even a revised manuscript will face desk rejection at top venues. This should be done before resubmission.

5. The novelty position (Required Revision #9) is subtle but important. The NOTCH3→NGF→NGFR/TRKA axis is not new in developmental biology (refs. 36–38 establish it in neural and cardiac contexts). What is new is its sustained activity in RA synovium and its role in pathological vascular maturation. The authors should state this explicitly so readers understand what is being claimed as RA-specific versus what is known biology relocated to a new tissue. This will also preempt a common reviewer objection.